Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease

Nour Majbour, Nishant Vaikath, Karin D. Van Dijk, Mustafa T. Ardah, Shiji Varghese, Louise B. Vesterager, Liliana P. Montezinho, Stephen Poole, Bared Safieh-Garabedian, Takahiko Tokuda, Charlotte E. Teunissen, Henk W. Berendse, Wilma D J Van De Berg, Omar Ali El-Agnaf

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Background: Despite decades of intensive research, to date, there is no accepted diagnosis for Parkinson's disease (PD) based on biochemical analysis of blood or CSF. However, neurodegeneration in the brains of PD patients begins several years before the manifestation of the clinical symptoms, pointing to serious flaw/limitations in this approach. Results: To explore the potential use of alpha-synuclein (α-syn) species as candidate biomarkers for PD, we generated specific antibodies directed against wide array of α-syn species, namely total-, oligomeric- and phosphorylated-Ser129-α-syn (t-, o- and p-S129-α-syn). Next we sought to employ our antibodies to develop highly specific ELISA assays to quantify α-syn species in biological samples. Finally we verified the usefulness of our assays in CSF samples from 46 PD patients and 48 age-matched healthy controls. We also assessed the discriminating power of combining multiple CSF α-syn species with classical Alzheimer's disease biomarkers. The combination of CSF o-/t-α-syn, p-S129-α-syn and p-tau provided the best fitting predictive model for discriminating PD patients from controls. Moreover, CSF o-α-syn levels correlated significantly with the severity of PD motor symptoms (r = -0.37). Conclusion: Our new ELISA assays can serve as research tools to address the unmet need for reliable CSF biomarkers for PD and related disorders.

Original languageEnglish
Article number7
JournalMolecular Neurodegeneration
Volume11
Issue number1
DOIs
Publication statusPublished - 19 Jan 2016

Fingerprint

alpha-Synuclein
Parkinson Disease
Biomarkers
Enzyme-Linked Immunosorbent Assay
Antibodies
Brain Diseases
Research
Alzheimer Disease

Keywords

  • Alpha synuclein
  • Amyloid oligomers
  • Biomarkers
  • Cerebrospinal fluid biomarkers
  • Parkinson's disease

ASJC Scopus subject areas

  • Molecular Biology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this

Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease. / Majbour, Nour; Vaikath, Nishant; Van Dijk, Karin D.; Ardah, Mustafa T.; Varghese, Shiji; Vesterager, Louise B.; Montezinho, Liliana P.; Poole, Stephen; Safieh-Garabedian, Bared; Tokuda, Takahiko; Teunissen, Charlotte E.; Berendse, Henk W.; Van De Berg, Wilma D J; Ali El-Agnaf, Omar.

In: Molecular Neurodegeneration, Vol. 11, No. 1, 7, 19.01.2016.

Research output: Contribution to journalArticle

Majbour, N, Vaikath, N, Van Dijk, KD, Ardah, MT, Varghese, S, Vesterager, LB, Montezinho, LP, Poole, S, Safieh-Garabedian, B, Tokuda, T, Teunissen, CE, Berendse, HW, Van De Berg, WDJ & Ali El-Agnaf, O 2016, 'Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease', Molecular Neurodegeneration, vol. 11, no. 1, 7. https://doi.org/10.1186/s13024-016-0072-9
Majbour, Nour ; Vaikath, Nishant ; Van Dijk, Karin D. ; Ardah, Mustafa T. ; Varghese, Shiji ; Vesterager, Louise B. ; Montezinho, Liliana P. ; Poole, Stephen ; Safieh-Garabedian, Bared ; Tokuda, Takahiko ; Teunissen, Charlotte E. ; Berendse, Henk W. ; Van De Berg, Wilma D J ; Ali El-Agnaf, Omar. / Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease. In: Molecular Neurodegeneration. 2016 ; Vol. 11, No. 1.
@article{d80a42f0e0b24f6f9c4e6a1cfc05dccf,
title = "Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease",
abstract = "Background: Despite decades of intensive research, to date, there is no accepted diagnosis for Parkinson's disease (PD) based on biochemical analysis of blood or CSF. However, neurodegeneration in the brains of PD patients begins several years before the manifestation of the clinical symptoms, pointing to serious flaw/limitations in this approach. Results: To explore the potential use of alpha-synuclein (α-syn) species as candidate biomarkers for PD, we generated specific antibodies directed against wide array of α-syn species, namely total-, oligomeric- and phosphorylated-Ser129-α-syn (t-, o- and p-S129-α-syn). Next we sought to employ our antibodies to develop highly specific ELISA assays to quantify α-syn species in biological samples. Finally we verified the usefulness of our assays in CSF samples from 46 PD patients and 48 age-matched healthy controls. We also assessed the discriminating power of combining multiple CSF α-syn species with classical Alzheimer's disease biomarkers. The combination of CSF o-/t-α-syn, p-S129-α-syn and p-tau provided the best fitting predictive model for discriminating PD patients from controls. Moreover, CSF o-α-syn levels correlated significantly with the severity of PD motor symptoms (r = -0.37). Conclusion: Our new ELISA assays can serve as research tools to address the unmet need for reliable CSF biomarkers for PD and related disorders.",
keywords = "Alpha synuclein, Amyloid oligomers, Biomarkers, Cerebrospinal fluid biomarkers, Parkinson's disease",
author = "Nour Majbour and Nishant Vaikath and {Van Dijk}, {Karin D.} and Ardah, {Mustafa T.} and Shiji Varghese and Vesterager, {Louise B.} and Montezinho, {Liliana P.} and Stephen Poole and Bared Safieh-Garabedian and Takahiko Tokuda and Teunissen, {Charlotte E.} and Berendse, {Henk W.} and {Van De Berg}, {Wilma D J} and {Ali El-Agnaf}, Omar",
year = "2016",
month = "1",
day = "19",
doi = "10.1186/s13024-016-0072-9",
language = "English",
volume = "11",
journal = "Molecular Neurodegeneration",
issn = "1750-1326",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease

AU - Majbour, Nour

AU - Vaikath, Nishant

AU - Van Dijk, Karin D.

AU - Ardah, Mustafa T.

AU - Varghese, Shiji

AU - Vesterager, Louise B.

AU - Montezinho, Liliana P.

AU - Poole, Stephen

AU - Safieh-Garabedian, Bared

AU - Tokuda, Takahiko

AU - Teunissen, Charlotte E.

AU - Berendse, Henk W.

AU - Van De Berg, Wilma D J

AU - Ali El-Agnaf, Omar

PY - 2016/1/19

Y1 - 2016/1/19

N2 - Background: Despite decades of intensive research, to date, there is no accepted diagnosis for Parkinson's disease (PD) based on biochemical analysis of blood or CSF. However, neurodegeneration in the brains of PD patients begins several years before the manifestation of the clinical symptoms, pointing to serious flaw/limitations in this approach. Results: To explore the potential use of alpha-synuclein (α-syn) species as candidate biomarkers for PD, we generated specific antibodies directed against wide array of α-syn species, namely total-, oligomeric- and phosphorylated-Ser129-α-syn (t-, o- and p-S129-α-syn). Next we sought to employ our antibodies to develop highly specific ELISA assays to quantify α-syn species in biological samples. Finally we verified the usefulness of our assays in CSF samples from 46 PD patients and 48 age-matched healthy controls. We also assessed the discriminating power of combining multiple CSF α-syn species with classical Alzheimer's disease biomarkers. The combination of CSF o-/t-α-syn, p-S129-α-syn and p-tau provided the best fitting predictive model for discriminating PD patients from controls. Moreover, CSF o-α-syn levels correlated significantly with the severity of PD motor symptoms (r = -0.37). Conclusion: Our new ELISA assays can serve as research tools to address the unmet need for reliable CSF biomarkers for PD and related disorders.

AB - Background: Despite decades of intensive research, to date, there is no accepted diagnosis for Parkinson's disease (PD) based on biochemical analysis of blood or CSF. However, neurodegeneration in the brains of PD patients begins several years before the manifestation of the clinical symptoms, pointing to serious flaw/limitations in this approach. Results: To explore the potential use of alpha-synuclein (α-syn) species as candidate biomarkers for PD, we generated specific antibodies directed against wide array of α-syn species, namely total-, oligomeric- and phosphorylated-Ser129-α-syn (t-, o- and p-S129-α-syn). Next we sought to employ our antibodies to develop highly specific ELISA assays to quantify α-syn species in biological samples. Finally we verified the usefulness of our assays in CSF samples from 46 PD patients and 48 age-matched healthy controls. We also assessed the discriminating power of combining multiple CSF α-syn species with classical Alzheimer's disease biomarkers. The combination of CSF o-/t-α-syn, p-S129-α-syn and p-tau provided the best fitting predictive model for discriminating PD patients from controls. Moreover, CSF o-α-syn levels correlated significantly with the severity of PD motor symptoms (r = -0.37). Conclusion: Our new ELISA assays can serve as research tools to address the unmet need for reliable CSF biomarkers for PD and related disorders.

KW - Alpha synuclein

KW - Amyloid oligomers

KW - Biomarkers

KW - Cerebrospinal fluid biomarkers

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=84954348724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954348724&partnerID=8YFLogxK

U2 - 10.1186/s13024-016-0072-9

DO - 10.1186/s13024-016-0072-9

M3 - Article

C2 - 26782965

AN - SCOPUS:84954348724

VL - 11

JO - Molecular Neurodegeneration

JF - Molecular Neurodegeneration

SN - 1750-1326

IS - 1

M1 - 7

ER -